Restricted accessResearch articleFirst published online 1995-08
Calculating therapeutic indices and therapeutic advantages for endotoxins and monophosphoryl lipid A: an evaluation of data from the scientific literature
This review article addresses the question of whether or not monophosphoryl lipid A offers a therapeutic advantage over smaller doses of endotoxin. Biological data were collected from a literature review and these were used to calculate therapeutic indices for monophosphoryl lipid A and endotoxin. Subsequent calculations yielded results which showed that, in humans and in other animals, monophosphoryl lipid A did have a therapeutic advantage over smaller doses of endotoxin.
Morrison DC, Ryan JLEndotoxins and disease mechanisms, Annu Rev Med1987; 38: 417-432.
3.
Reitschel ET, Braude H., Braude L. et al. Lipid A, the endotoxic center of bacterial lipopolysaccharides: relation of chemical structure to biological activity. In: Detection of bacterial endotoxins with the Limulus amebocyte lysate test. New York: Alan R Liss, 1987: 25-53.
4.
Freedman HH, Sultzer BMDissociation of antitoxic and immunogenic activities of endotoxin by acetylation . Ann NY Acad Sci1966; 133: 580-585.
5.
Bertok L.Stimulation of nonspecific resistance by radio-detoxified endotoxin. In: Friedman H, Klein TW, Nakano M, Nowotny A eds. Endotoxin. New York: Plenum, 1990: 677-680.
6.
Niwa M., Milner KC, Ribi E., Rudbach JAAlteration of physical, chemical, and biological properties of endotoxin by treatment with mild alkali. J Bacteriol1969 ; 97: 1069-1077.
7.
Myers KR, Truchot AT, Ward J., Hudson Y., Ulrich T.A critical determinant of lipid A endotoxic activity. In: Nowotny A, Spitzer JJ, Ziegler EJ eds. Cellular and molecular aspects of endotoxin reactions. New York: Elsevier, 1990: 145-156.
8.
Nowotny A. Microbiology.Endotoxoid preparations. Nature1963; 197: 721-722.
9.
Johnson AG, Nowotny A.Relationship of structure to function in bacterial O antigens. III. Biological properties of endotoxoids. J Bacteriol1964 ; 87: 809-814.
10.
Ribi E., Cantrell J., Feldner T., Myers K., Peterson J. In: Levie L, Bonventre PF, Morello JA et al eds. Bacterial Lipopolysaccharides. Washington DC: American Chemical Society, 1986: 3-17.
11.
Gilman AG, Rall TW, Nies AS, Taylor Peds.Goodman and Gilman's the pharmacological basis of therapeutics. New York: Pergamon, 1990: 68.
12.
Gosselin RE, Hodge HC, Smith RP, Gleason MNClinical toxicology of commercial products, 4th edn. Baltimore: Williams & Wilkins, 1976: 296.
13.
Takayama K., Qureshi N., Ribi E., Cantrell JL, Amano K.Use of endotoxin in cancer immunotherapy and characterization of its nontoxic but active lipid A components. In: Anderson L, Unger F eds. Bacterial Lipopolysaccharides: Structure, Synthesis, and Biological Activities. Washington DC: American Chemical Society, 1983: 219-233.
14.
Takayama K., Qureshi N., Ribi E., Cantrell JLSeparation and characterization of toxic and nontoxic forms of lipid A. Rev Infect Dis1984; 6: 439-443.
15.
Ribi E., Cantrell J., Takayama K.A new immunomodulator with potential clinical applications: monophosphoryl lipid A, a detoxified endotoxin. Clin Immunol News1985; 6: 33-36.
16.
Rudbach JA, Cantrell JLStudies of the structure and function relationships of endotoxin. In: Nowotny A, Spitzer JJ, Ziegler EJ eds. Cellular and Molecular Aspects of Endotoxin Reactions. New York: Elsevier, 1990: 33-39.
17.
Greisman SE , Hornick RBComparative pyrogenic reactivity of rabbit and man to bacterial endotoxin. Proc Soc Exp Biol Med1969; 131: 1154-1158.
18.
Pruzanski W. , Mackensen A., Engelhardt R., Stefanski E., Vadas P.Induction of circulating phospholipase A2 activity by intravenous infusion of endotoxin in patients with neoplasia. J Immunother1992; 12: 242-246.
19.
Granowitz EV , Santos AA, Poutsiaka DD et al. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet1991; 338: 1423-1424.
20.
Atkins E.Pathogenesis of fever. Physiol Rev1960; 40: 580-646.
21.
Mechanic RC , Frei E. III, Landy M., Smith WWQuantitative studies of human leukocyte and febrile response to single and repeated doses of purified bacterial endotoxin . J Clin Invest1962; 41: 162-172.
22.
Favorite GO , Morgan HREffects produced by the intravenous injection in man of a toxic antigenic material derived from Eberthella typhosa: clinical, hematological, chemical and serological studies. J Clin Invest1942; 21:589-599.
23.
Wolff SMBiologic effects of bacterial endotoxins in man. J Infect Dis1973; 128: 251-256.
24.
Engelhardt R., Mackensen A., Galanos C., Andreesen R.Biological response to intravenously administered endotoxin in patients with advanced cancer. J Biol Resp Modif1990; 9: 480-491.
25.
Greisman SE , Homick RBMechanisms of endotoxin tolerance with special reference to man. J Infect Dis1973; 128 (suppl): S265-S276.
26.
Greisman SE , Wagner Jr HN, Iio M., Hornick RBMechanisms of endotoxin tolerance. II. Relationship between endotoxin tolerance and reticuloendothelial system phagocytic activity in man. J Exp Med1964; 119: 241-264.
27.
Vosika GJ, Barr C., Gilbertson D.Phase-I study of intravenous modified lipid A. Cancer Immunol Immunother1984; 18: 107-112.
28.
Morrison DC , Ryan JLEndotoxins and disease mechanisms. Annu Rev Med1987; 38: 417-432.
29.
Granowitz EV , Porat R., Mier JW et al. Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans . J Immunol1993; 151: 1637-1645.
30.
Martich GD, Danner RL, Ceska M., Suffredini AFDetection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med1991; 173: 1021-1024.
31.
Fong Y., Moldawer LL, Marano M. et al. Endotoxemia elicits increased circulating β2IFN/IL-6 in man. J Immunol1989; 142: 2321-2324.
32.
Michie HR, Manogue KR, Spriggs DR et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med1988; 318: 1481-1486.
33.
Suffrendini AF, Fromm RE, Parker MM et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med1989; 321: 280-298.
34.
Rudbach JA, Ulrich JT, Von Eschen KB, Beatty JDUse of monophosphoryl lipid A as a prophylactic for sepsis and shock. In: Faist E, Meakins JL, Schildberg FW eds. Host Defense Dysfunction in Trauma, Shock and Sepsis. New York: Springer-Verlag, 1993: 779-782.
35.
Morgan HRResistance to the action of the endotoxins of enteric bacilli in man. J Clin Invest1948; 27: 706-709.
36.
Neate EV, Greenhalgh AM, McPhee DA, Crowe SMBacterial lipopolysaccharide mediates the loss of CD4 from the surface of purified peripheral blood monocytes. Clin Exp Immunol1992; 90: 539-544.
37.
Rudbach JA, Myers KR, Rechtman DJ, Ulrich JTProphylactic use of monophosphoryl lipid A in patients at risk for sepsis . In: Levin J, van Deventer SJH, van der Poll T, Sturk A eds. Bacterial Endotoxins: Basic Science and Anti-Sepsis Strategies. New York: Wiley-Liss, 1994: 107-124.
38.
Bennett JA, Peters JH, Chudacoff R., McKneally MFEndogenous production of cytotoxic factors in serum of BCG-primed mice by monophosphoryl lipid A, a detoxified form of endotoxin. J Biol Resp Modif1988; 7: 65-76.
39.
Kiener PA, Marek F., Rodgers G., Lin P-F., Warr G., Desiderio J.Induction of tumor necrosis factor, IFN-γ, and acute lethality in mice by toxic and non-toxic forms of lipid A. J Immunol1988; 141: 870-874.
40.
Ulrich JT, In-house data.
41.
Takada H., Kotani S.Structural requirements of lipid A for endotoxicity and other biological activities. CRCCrit Rev Microbiol1989; 16: 477-523.
42.
Johnson AG, Tomai MA, Chen YF, Odean M.A comparison of the immunomodulating properties of two forms of monophosphoryl lipid A analogues. J Immunother1991; 10: 398-404.
43.
Grundmann H-J. , Hähnle U., Hegenscheid B., Sahlmüller G., Bienzle U., Blitstein-Willinger E.Inhibition of endotoxin-induced macrophage tumor necrosis factor expression by a prostacyclin analogue and its beneficial effect in experimental lipopolysaccharide intoxication. J Infect Dis1992; 165: 501-505.
44.
Galanos C., Freudenberg MA, Reutter W.Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA1979; 76: 5939-5943.
45.
Evans GF, Zuckerman SHGlucocorticoid-dependent and -independent mechanisms involved in lipopolysaccharide tolerance. Eur J Immunol1991; 21: 1973-1979.
46.
Qureshi N., Takayama K., Ribi E.Purification and structural determination of nontoxic lipid A obtained from lipopolysaccharide of Salmonella typhimurium. J Biol Chem1982; 257: 11808-11815.
47.
Henricson BE , Benjamin WR, Vogel SNDifferential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun1990; 59: 2429-2437.
Gustafson GL , Rhodes MJA rationale for the prophylactic use of monophosphoryl lipid A in sepsis and septic shock. Biochem Biophys Res Commun1992; 182: 269-275.
50.
Madonna GS, Peterson JE, Ribi EE, Vogel SNEarly-phase endotoxin tolerance: induction by a detoxified lipid A derivative, monophosphoryl lipid A. Infect Immun1986; 52: 6-11.
51.
Mengozzi M. , Ghezzi P.Cytokine down-regulation in endotoxin tolerance . Eur Cytokine Netw1993; 4: 162-172.
52.
Madonna GS, Vogel SNInduction of early-phase endotoxin tolerance in athymic (nude) mice, B-cell-deficient (xid) mice, and splenectomized mice. Infect Immun1986; 53: 707-710.
53.
Williams Z. , Hertogs CF, Pluznik DHUse of mice tolerant to lipopolysaccharides to demonstrate requirement of cooperation between macrophages and lymphocytes to generate lipopolysaccharide-induced colony-stimulating factor in vivo. Infect Immun1983; 41: 1-5.
54.
Madonna GS, Vogel SNEarly endotoxin tolerance is associated with alterations in bone marrow-derived macrophage precursor pools. J Immunol1985 ; 135: 3763-3771.
55.
Loppnow H., Braude H., Dürrbaum I. et al. IL-1 induction-capacity of defined lipopolysaccharide partial structures. J Immunol1989; 142: 3229-3238.
56.
Ribi E., Cantrell JL, Takayama K., Ribi HO, Myers KR, Qureshi N.Modulation of humoral and cell-mediated immune responses by a structurally established nontoxic lipid A. In: Szentivanyi A, Friedman H eds. Immunobiology and Immunopharmacology of Bacterial Endotoxins. New York : Plenum, 1986: 407-420.
57.
Baker PJEffect of endotoxin on suppressor T cell function. Immunobiology1993; 187: 372-381.
58.
Garg M., Subbarao B.Immune responses of systemic and mucosal lymphoid organs to Pnu-Imune vaccine as a function of age and the efficacy of monophosphoryl lipid A as an adjuvant . Infect Immun1992; 60: 2329-2336.
59.
Ulrich JT, Masihi KN, Lange W.Mechanisms of nonspecific resistance to microbial infections induced by trehalose dimycolate (TDM) and monophosphoryl lipid A (MPL). Adv Biosci1988; 68: 167-178.
60.
Alving CRLipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology1993; 187: 430-446.
61.
Takayama K., Qureshi N., Ribi E., Cantrell JL, Amano K.Use of endotoxin in cancer immunotherapy and characterization of its nontoxic but active lipid A components. In: Anderson L, Unger F eds. Bacterial Lipopolysaccharides: Structure, Synthesis, and Biological Activities. Washington DC: American Chemical Society, 1983: 219-233.
62.
Richards RL , Swartz Jr GM, Schultz C. et al. Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminum hydroxide and non-pyrogenic liposomal lipid A. Vaccine1989; 7: 506-512.
63.
Ribi E., Cantrell JL, Takayama K., Qureshi N., Peterson J., Ribi HOLipid A and immunotherapy. Rev Infect Dis1984; 6: 567-572.
64.
Sosynski D. , Kozak W., Szewczenko M.Course of fever response to repeated administration of sublethal doses of lipopolysaccharides, polyinosinic: polycytidylic acid and muramyl dipeptide to rabbits. Experientia1991; 47: 43-47.
65.
Johnson AG, Gaines S., Landy M.Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide. J Exp Med1956; 103: 225-246.
66.
Hildenbrandt J., Lam C., Loibner H. et al. Chemical synthesis of analogues and some structure and activity relationships. In: Nowotny A, Spitzer JJ, Ziegler EJ eds. Cellular and Molecular Aspects of Endotoxin Reactions. New York: Elsevier, 1990: 129-143.
67.
Hochstein HD , Fitzgerald EA, McMahon FG, Vargas R.Properties of US standard endotoxin (EC-5) in human male volunteers. J Endotox Res1994 ; 1: 52-56.
